<DOC>
	<DOCNO>NCT01930331</DOCNO>
	<brief_summary>Phase IV , single center , 2 arm randomize control , open label study . Study conduct period 42 day determine safety , tolerability , pharmacokinetics efficacy ARCO .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Efficacy ARCO</brief_title>
	<detailed_description>Evaluation safety tolerability administration ARCO Eurartesim term blood biochemistry , full blood count , ECG assessment , vital sign adverse event profile patient uncomplicated P. falciparum malaria . Dihydroartemisinin/piperaquine use comparator .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<mesh_term>Artemisinine</mesh_term>
	<criteria>1 . Written informed consent , accordance local practice , provide patient , child provide either parent legal representative addition child provide assent . 2 . Male female patient age 6 60 year ( inclusive ) 3 . Body weight 20 kg 90 kg ( inclusive ) 4 . Presence monoinfection P. falciparum ( 1,000 100,000 asexual count/µl blood ) microscopically confirm . 5 . Fever , define axillary temperature ≥ 37.5°C ≤ 39.5°C 6 . Ability swallow oral medication 7 . Ability willingness adhere study procedure access health facility . 8 . Agree undergo study relate procedure include hospitalize minimum 3 day ( 0,1 2 ) , follow 42 day . 1 . Patients sign symptom severe/complicated malaria describe WHO guideline ( Third Edition 2012 ) management severe malaria ( 6 ) ( Appendix 1 ) 2 . Mixed Plasmodial infection . 3 . Severe vomiting , define three time 24 hour prior inclusion study inability tolerate oral treatment . 4 . Severe diarrhoea define 3 watery stool per day . 5 . Presence serious chronic clinical condition require hospitalization . 6 . Known history evidence clinically significant disorder cardiovascular ( include arrhythmia , QTcF QTcB interval great equal 450 msec ) , respiratory ( include active tuberculosis ) , history jaundice , hepatic , renal , gastrointestinal , immunological , neurological ( include auditory ) , endocrine , infectious , malignancy , psychiatric , history convulsion abnormality ( include head trauma ) . 7 . Family history sudden death congenital prolongation QT interval clinical condition know prolong QT interval . 8 . Known congenital prolongation QTinterval clinical condition know prolong QT interval . 9 . History symptomatic cardiac arrhythmia clinically relevant bradycardia . 10 . Any predisposing cardiac condition arrhythmia severe hypertension , leave ventricular hypertrophy ( include hypertrophic cardiomyopathy ) congestive cardiac failure accompany reduce left ventricle ejection fraction . 11 . Electrolyte disturbance , particularly hypokalaemia , hypocalcaemia hypomagnesaemia . 12 . Any treatment induce lengthen QT interval , : i. Antiarrhythmics ( e.g . amiodarone , disopyramide , dofetilide , ibutilide , procainamide , quinidine , hydroquinidine , sotalol ) ii . Neuroleptics ( e.g . phenothiazine , sertindole , sultopride , chlorpromazine , haloperidol , mesoridazine , pimozide , thioridazine ) iii . Antidepressive agent , certain antimicrobial agent , include agent follow class macrolides ( e.g . erythromycin , clarithromycin ) , fluoroquinolones ( e.g . moxifloxacin , sparfloxacin ) , imidazole triazole antifungal agent , also pentamidine saquinavir iv . Certain nonsedating antihistamine ( e.g . terfenadine , astemizole , mizolastine ) , cisapride , droperidol , domperidone , bepridil , diphemanil , probucol , levomethadyl , methadone , vinca alkaloid , arsenic trioxide 13 . Known history hypersensitivity , allergic adverse reaction artemisinin contain compound , piperaquine naphthoquine excipients contain ARCO Eurartesim . 14 . Antimalarial treatment different antimalarial drug follow i. Piperaquinebased compound , mefloquine , naphthoquine sulphadoxine/pyrimethamine ( SP ) within previous 3 month , ii . Amodiaquine chloroquine within previous 6 week , quinine , halofantrine , lumefantrinebased compound iii . Any antimalarial treatment , antibiotic antimalarial activity ( include cotrimoxazole , tetracycline , quinolones fluoroquinolones , azithromycin ) herbal product , within past 14 day 15 . Have receive investigational drug within past 6 week . 16 . Liver function test : . If Total Bilirubin normal , exclude patient liver function test ASAT/ALAT ≥ 3xULN ii . If Total Bilirubin &gt; 1 ≤ 1.5xULN , exclude patient ASAT/ALAT ≥2xULN . iii . Total Bilirubin &gt; 1.5xULN 17 . Hb level 9 g/dL . 18 . Serum creatinine level 2 time upper limit normal range absence dehydration . In case important dehydration creatinine low 2X ULN oral/parenteral rehydration . 19 . Female patient must neither pregnant ( demonstrated negative serum pregnancy test ) lactating , must willing take measure become pregnant study period safety followup period . 20 . Previous participation malaria vaccine trial receive malaria vaccine circumstance</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Uncomplicated Plasmodium falciparum Malaria</keyword>
</DOC>